[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100576466":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":40,"responsibleParty":61,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":72,"enrollmentInfo":73,"targetDuration":25,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":87,"whyStopped":25,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Siriraj Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"The budesonide nasal irrigation group","EXPERIMENTAL","The participant in this group used a solution containing 1 milligram of budesonide mixed with 240 milliliters of normal saline in a squeeze bottle (Cleanoze®) for nasal irrigation. The procedure will be performed once daily while leaning slightly forward over a sink.",[13],"Drug: The budesonide nasal irrigation",{"label":15,"type":16,"description":17,"interventionNames":18},"The budesonide nasal spray group","ACTIVE_COMPARATOR","The participant in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).",[19],"Drug: The budesonide nasal spray",[21,26],{"type":22,"name":23,"description":11,"armGroupLabels":24,"otherNames":25},"DRUG","The budesonide nasal irrigation",[9],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"The budesonide nasal spray","The participants in this group used a nasal spray containing 64 micrograms of budesonide per spray, with two sprays per nostril administered twice daily (morning and evening).",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Navarat Kasemsuk, M.D.","CONTACT","+66870890444","mintkus32@hotmail.com",{"name":37,"role":33,"phone":38,"phoneExt":25,"email":39},"Pongsakorn Tantilipikorn, M.D., PhD.","+66818363074","pongsakorn.tan@mahidol.ac.th",[41],{"facility":42,"status":25,"city":43,"state":25,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"Siriraj Hospital, Mahidol University","Bangkok","10700","Thailand","TH",{"type":48,"coordinates":49},"Point",[50,51],100.50144,13.75398,{"lat":51,"lon":50},[54,57,59],{"name":55,"role":33,"phone":56,"phoneExt":25,"email":35},"Navarat Kasemsuk","0870890444",{"name":58,"role":33,"phone":38,"phoneExt":25,"email":39},"Pomgsakorn Tantilipikorn, M.D., PhD.",{"name":32,"role":60,"phone":25,"phoneExt":25,"email":25},"PRINCIPAL_INVESTIGATOR",{"type":60,"investigatorFullName":55,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"Dr.","100576466","phase-4-budesonide-irrigation-in-allergic-rhinitis-100576466",false,"NCT06785662","Budesonide Irrigation in Allergic Rhinitis","The Efficacy of Budesonide Nasal Irrigation in Allergic Rhinitis Patients: A Randomized, Controlled Trial.","Inclusion Criteria:\n\n* Participants aged 18-60 years diagnosed with perennial allergic rhinitis based on ARIA guidelines, who have previously consistently used intranasal corticosteroids for at least 2 weeks with inadequate control of nasal inflammation defined by a VAS score of ≥5 out of 10 and requiring dosage adjustment. Noted that proper technique should have been confirmed through retrospective questioning.\n\nExclusion Criteria:\n\n* Those with a history of sinus surgery, nasal or sinus tumors (including polyps), significant deviated nasal septum causing symptoms, oral corticosteroid uses for any indication, immunodeficiency, pregnancy, breastfeeding, or suspected fungal sinusitis indicated by ischemic nasal tissue, fungal masses, bone erosion, or calcifications on imaging were excluded. Participants would be withdrawn if severe complications arise from the use of topical budesonide.","ALL","18 Years","60 Years",{"count":74,"type":75},78,"ESTIMATED","INTERVENTIONAL",[78],"PHASE4","Topical nasal steroids are significant therapeutic options for allergic rhinitis (AR). The distribution of intranasal steroid spray (INS) administration is less than that of irrigation. However, the available data on steroid nasal irrigation is limited. This article aims to evaluate the efficacy and adverse effects (AEs) of steroid irrigation in AR patients.",[81],"Allergic Rhinitis",[83,84,85,86],"intranasal corticosteroid","budesonide nasal irrigation","Budesonide nasal spray","Allergic rhinitis","NOT_YET_RECRUITING","2025-01-20",{"date":90,"type":91},"2025-01-21","ACTUAL",{"date":93,"type":75},"2025-02-12",{"date":95,"type":75},"2026-06-01",{"name":5,"class":6},1]